TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • March 4, 2021

SILVER SPRING, MD—The FDA approved an extended indication for Entresto (sacubitril/valsartan), making it the first and only approved therapy in the US to treat adult patients diagnosed with heart failure. This includes patients suffering from heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. The approval of this expanded indication will also enable the potential treatment of more adults with left ventricular ejection fraction below normal. Entresto is manufactured by Novartis, East Hanover, NJ.